A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

~9 mi. (Obninsk, Russia, +383 more cities)

Federal State Institution Medical Radiology Research Center

ER Negative, +2 more biomarkers

Breast Carcinoma

atezolizumab, +4 more drugs

chemotherapy, +1 more type

Sasanlimab (PF-06801591) in Combination With BCG or as Single Agent in Participants With High-Risk Non-Muscle Invasive Bladder Cancer

~9 mi. (Obninsk, Russia, +153 more cities)

A.Tsyb Medical Research Radiological Center of the Ministry of Health of the Russian Federation

Bladder Urothelial Carcinoma, +2 more conditions

BCG solution, +1 more drug

immunotherapy

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

~9 mi. (Obninsk, Russia, +93 more cities)

National Medical Research Radiology Centre ( Site 0869)

Bladder Carcinoma, +1 more condition

cisplatin, +4 more drugs

chemotherapy, +3 more types

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

~9 mi. (Obninsk, Russia, +190 more cities)

MRRC n.a. A.F. Tsyb - branch of FSBI "NMRC of Radiology" Minzdrav Russia, +2 more facilities

ATM Loss, +27 more biomarkers

Prostate Adenocarcinoma

enzalutamide, +1 more drug

hormone therapy, +1 more type

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

~9 mi. (Obninsk, Russia, +143 more cities)

National medical research center of radiology Obninsk

RET Mutation

Thyroid Gland Medullary Carcinoma

selpercatinib

targeted therapy

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

~55 mi. (Podolsk, Russia, +89 more cities)

Podolsk Regional Clinical Hospital ( Site 1907)

ER Positive, +2 more biomarkers

Breast Carcinoma

capecitabine, +4 more drugs

chemotherapy, +1 more type

Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

~64 mi. (Kaluga, Russia, +126 more cities)

Kaluga Regional Clinical Oncology Center ( Site 0424)

Adenocarcinoma of the Gastroesophageal Junction, +1 more condition

FOLFOX regimen, +3 more drugs

chemotherapy, +2 more types

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

~64 mi. (Kaluga, Russia, +201 more cities)

Kaluga Regional Clinical Hospital /ID# 221211

Myelodysplastic Syndromes

azacitidine, +1 more drug

chemotherapy

A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

~70 mi. (Krasnogorsk, Russia, +93 more cities)

MEDSI Clinical Hospital on Pyatnitsky Highway-Departmentof Antitumor Drug therapy ( Site 2618)

Clear Cell Renal Cell Carcinoma

belzutifan, +1 more drug

targeted therapy

Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)

~70 mi. (Krasnogorsk, Russia, +105 more cities)

MEDSI Clinical Hospital on Pyatnitsky Highway-Departmentof Antitumor Drug therapy ( Site 1129)

Colorectal Adenocarcinoma

bevacizumab, +1 more drug

targeted therapy

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65)

~70 mi. (Krasnogorsk, Russia, +13 more cities)

Moscow City Oncology Hospital #62 ( Site 2214)

Fallopian Tube Carcinoma, +2 more conditions

bevacizumab, +3 more drugs

chemotherapy, +2 more types

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

~70 mi. (Krasnogorsk, Russia, +105 more cities)

MEDSI Clinical Hospital on Pyatnitsky Highway-Departmentof Antitumor Drug therapy ( Site 1216)

ATM Loss, +62 more biomarkers

Breast Carcinoma, +2 more conditions

olaparib

targeted therapy